
***TRI with Two Endeavor stents for
High Risk Patient who needs
Elective Vascular Surgery***


Sung Yun Lee
Inje University Ilsan Paik Hospital

Case summary

0525875

- *Male / 64 years*
- *C/C:* Exertional pain and dyspnea, CCS II
with Limited ordinary activity due to Leg pain on walking
onset : 2 months ago
- *Risk factor :* Diabetes treated with Insulin for 20 years
Hypertension
Smoking 2 packs/day for 20 years
- *Past Medical History:* Poliomyelitis since 4 yrs old
- *Echo:* Akinesia of posterolateral wall
Hypokinesia of mid~ apical inferior wall
Hypokinesia of mid ~ apical Anterior wall
LVEF = 40%

EKG



CT Angio. for Low Extremity





Complete occlusion, right superficial femoral artery, both ATA and left peroneal artery.

Multifocal stenosis, right deep femoral artery and left femoral artery and left PTA.


Diffuse muscle atrophic change with decreased blood flow, left lower extremity.




MD CT CAG






H
R
P







**Diagonal branch feeding
the collateral to distal LCX**

Future Plan

- **Dual Anti-platelet Therapy**
 - Aspirin 200 mg
 - Clopiogrel 75 mg

- **Elective Surgery for Low Extremity**
 - Postpone 3 months after PCI
 - Quit Clopidogrel
 - Maintain Aspirin
 - I.V. Heparin just after Bypass surgery

SENS Study

Although current guidelines recommend DAPT for 12 months, the SENS study concluded that in the patients evaluated, Endeavor “appears to be safe and feasible in patients undergoing non-cardiac surgical procedure” after 3 months following stent implantation.

Variables	Early surgery group (0-3 months, n=34)	Late surgery group (3-12 months, n=160)	p-value
Age(yrs)/Male(%)	62.2/63.5	63.1/50.9	NS
Lesion type (B2/C) (%)	73.6	72.8	NS
Stent number	1.4	1.5	NS
Mean stent diameter (mm)	3.11±0.52	3.08±0.47	NS
Total stent length (mm)	33.0±16.7	29.2±19.5	NS
Major surgery (%)	20.5	22.8	NS
Days from stenting to surgery	56.5	233.7	<0.001
DAP withdrawal (days)	13.4	14.8	NS
MACE (%)	8.9 (2 Death, 1 MI)	0.6 (1 MI)	<0.001

SENS: Kim et al. ACC 2009.
Note – ST data were not reported

For distribution in the USA only. © 2009 Medtronic, Inc. All rights reserved. UC200905148EN

Full Text View

[Tabular View](#)

[No Study Results Posted](#)

[Related Studies](#)

The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent (DATE)

This study is currently recruiting participants.

Verified by Samsung Medical Center, February 2009

First Received: January 3, 2007 Last Updated: February 11, 2009 [History of Changes](#)

Sponsors and Collaborators:	Samsung Medical Center Medtronic
Information provided by:	Samsung Medical Center
ClinicalTrials.gov Identifier:	NCT00418860

▶ Purpose

The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.

Condition	Intervention
Coronary Artery Disease	Drug: Aspirin, Clopidogrel

Preliminary data at 6 months (92.4% F/U) / 1 year (34% F/U)
 single vessel disease 88% one lesion treatment 89% one stent 86%

Events

Death 0.4%, Cardiac death 0.4%

3 Months of dual antiplatelet agent : stent thrombosis 0.35%